The Hybrid Compounds as Multi-target Ligands for the Treatment of Alzheimer's Disease: Considerations on Donepezil.
Amyloid beta
Antioxidant
Cholinesterase
Donepezil
Hybrid drug design
MAO-B
Metal-chelation
Journal
Current topics in medicinal chemistry
ISSN: 1873-4294
Titre abrégé: Curr Top Med Chem
Pays: United Arab Emirates
ID NLM: 101119673
Informations de publication
Date de publication:
04 Mar 2022
04 Mar 2022
Historique:
received:
30
11
2020
revised:
31
08
2021
accepted:
11
11
2021
pubmed:
13
11
2021
medline:
18
3
2022
entrez:
12
11
2021
Statut:
ppublish
Résumé
The strategies to combat Alzheimer's Disease (AD) have been changing with respect to the failures of many drug candidates assessed in clinical studies, the complex pathophysiology of AD, and the limitations of the current drugs employed. So far, none of the targets, either validated or nonvalidated, have been shown to be purely causative in the generation and development of AD. Considering the progressive and the neurodegenerative characteristics of the disease, the main strategy has been based on the design of molecules capable of showing activity on more than one receptor, and it is defined as multi-target ligand design strategy. The hybrid molecule concept is an outcome of this approach. Donepezil, as one of the currently employed drugs for AD therapy, has also been utilized in hybrid drug design studies. This review has aimed to present the promising donepezil-like hybrid molecules introduced in the recent period. Particularly, multi-target ligands with additional activities concomitant to cholinesterase inhibition are preferred.
Identifiants
pubmed: 34766890
pii: CTMC-EPUB-118819
doi: 10.2174/1568026621666211111153626
doi:
Substances chimiques
Cholinesterase Inhibitors
0
Ligands
0
Donepezil
8SSC91326P
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
395-407Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.